Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study
Introduction Geographic atrophy (GA) is the advanced form of the non-neovascular (‘dry’) type of age-related macular degeneration (AMD). Previously untreatable, complement inhibitors delivered by regular intravitreal injections have recently been demonstrated to slow down the progression of GA lesio...
Saved in:
| Main Authors: | David P Crabb, Deanna J Taylor, Christiana Dinah, Mandeep Sekhon, Jamie Enoch, Arevik Ghulakhszian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-01-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/1/e075713.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Implementing patient and public involvement (PPI) in eye research: reflections from developing a research study on Geographic Atrophy treatment acceptability
by: Jamie Enoch, et al.
Published: (2025-08-01) -
Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad Pegol
by: Rush RB, et al.
Published: (2025-03-01) -
Characterizing Patient Perceptions of Living with Geographic Atrophy: The Global Geographic Atrophy Insights Survey
by: Bakri SJ, et al.
Published: (2024-12-01) -
Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials
by: Huan Wang, et al.
Published: (2024-11-01) -
Compass Fundus-Guided Perimetry in Geographic Atrophy
by: Roberta Farci, et al.
Published: (2022-01-01)